India aims for $100 billion biotech industry by 2025

Serving the twin purposes of creating a globally competitive biopharmaceutical industry that addresses India's major concerns around barriers to affordable healthcare, India's Department of Biotechnology (DBT) is set to roll out biosimilar drugs for diseases such as cancer, diabetes and rheumatoid arthritis, reports The Pharma Letter’s India correspondent.

Though India has been an active player in the global pharmaceutical industry and has contributed towards making life saving drugs and low-cost pharmaceutical products, the Indian biopharmaceutical industry appears to be around 10-15 years behind some of its neighboring countries like China and Korea.

The government has identified that the lacuna primarily exists due to disconnected centers of excellence, less focus on translational research and uncertain funding.